<DOC>
	<DOCNO>NCT01126463</DOCNO>
	<brief_summary>This study determine maximum tolerate dose recommend 188Re-SSS Lipiodol activity hepatic intra-arterial injection patient hepato-cellular carcinoma . The new radioactive isotope 188Rhenium associate Lipiodol expect reduce radioprotection constraint hence duration hospitalisation protect room 8 1 day .</brief_summary>
	<brief_title>188RE-SSS Lipiodol Treat HepatoCellular Carcinomas</brief_title>
	<detailed_description>Hepatocellular carcinoma one prevalent primary cancer many country . In France , mortality due HCC viral C cirrhosis go increase 150 % men 200 % woman 2020 . Consequently , HCC problem public health . The current treatment HCC mainly palliative chemoembolization intra-arterial radiotherapy , intra-arterial targeted radiotherapy best tolerate method ( iodine-131-labelled lipiodol commonly use ) . However , since 2007 , new therapeutic approach consider oral sorafenib , anti-angiogenic drug increase slightly survival patient . The key efficient treatment HCC presumably co-treatment sorafenib intra-arterial radiotherapy . The 131I-lipiodol good candidate present disadvantage : require hospitalization radionuclide therapy room one week . Therefore , necessary find new radioactive labellings lipiodol . In objective , 188Re-SSS lipiodol , new radioactive label stable complex develop . It short half-life tiny amount gamma radiation compare 131I-lipiodol , allow reduce hospitalization protect room 8 day one day . The aim study determine Maximum Tolerated Dose thus recommend activity 188Re-SSS lipiodol intra-arterial injection patient HCC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>Adult 18 , WHO performance status ≤ 2 , Hepatocellular carcinoma histologically cytologically proven , association liver tumor chronic hepatopathy AFP &gt; 400 ng/ml , tumorous hepatic formation consider hypervascularised least 2 method image cirrhotic patient , Non operable , non resectable , non transplantable , non accessible percutaneous treatment tumor , Measurable tumor , uni multinodular , take less 50 % hepatic volume , Stage A C BCLC classification ( stage 0 4 CLIP ) : No thrombosis portal vein , therapeutic escape intolerance cause end treatment contraindication sorafenib If thrombosis portal vein , therapeutic escape Lipiocis , Possibility treatment intraarterial radiotherapy decision Multidisciplinary Committee , Written inform consent Patient stage ≥ 3 toxicity CTCAE version 4 Stage D classification BCLC Acute impairment hepatic function ( ChildPugh B9 C ) Grade III Hepatocarcinoma Okuda classification Encephalopathy trouble even moderate cognitive function Advanced chronic respiratory insufficiency Creatinine clearance &lt; 55 ml/min , polynuclear neutrophil &lt; 1500 G/L , platelets &lt; 50 G/L , prothrombin &lt; 40 % ( INR &gt; 2,3 ) Contraindication intraarterial administration Patients ca n't follow psychological geographic reason Patients dependant another person daily care Urinary incontinence Progressive cancer Pregnant breastfeed woman , use adequate effective contraception method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>lipiodol</keyword>
	<keyword>rhenium</keyword>
	<keyword>Non operable Hepatocellular carcinoma</keyword>
</DOC>